Literature DB >> 11459001

Dopamine activates HIV in chronically infected T lymphoblasts.

C Scheller1, S Sopper, C Jassoy, V ter Meulen, P Riederer, E Koutsilieri.   

Abstract

HIV infection is associated with a marked vulnerability of the dopaminergic system. We found recently that dopaminergic substances increase brain pathology in the simian model of HIV infection. In the current study we used the chronically HIV-infected T-lymphoblasts ACH-2 to elucidate the effects of dopamine (DA) on HIV infection. Cells were exposed to various concentrations of DA for 24 hours. Flow cytometry measurements demonstrated that DA induced a concentration-dependent HIV activation. To study the mechanism of action of DA, cells were treated besides DA with glutathione, one of the main components of cellular defense mechanisms against oxidative stress as well as its indirect precursor N-acetylcysteine. Treatment with these antioxidants attenuated DA-induced-HIV activation indicating that changes in cellular redox states might have been the causative factor for the observed effect. Our data suggest that HIV activation is tightly linked to intracellular oxidant/antioxidant levels and that excessive DA exposure may modulate cellular vulnerability to HIV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11459001     DOI: 10.1007/s007020070012

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  13 in total

1.  Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities.

Authors:  Linda Chang; Thomas Ernst; Oliver Speck; Charles S Grob
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

2.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

3.  National Institute on Drug Abuse symposium report: drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; Jerry Frankenheim; Albert Avila; Roger Sorensen; Joni Rutter
Journal:  J Neurovirol       Date:  2013-03-01       Impact factor: 2.643

Review 4.  Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Authors:  Vishnudutt Purohit; Rao Rapaka; David Shurtleff
Journal:  Mol Neurobiol       Date:  2011-07-01       Impact factor: 5.590

5.  Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse.

Authors:  Peter J Gaskill; Tina M Calderon; Aimée J Luers; Eliseo A Eugenin; Jonathan A Javitch; Joan W Berman
Journal:  Am J Pathol       Date:  2009-08-06       Impact factor: 4.307

6.  The dopamine-related polymorphisms BDNF, COMT, DRD2, DRD3, and DRD4 are not linked with changes in CSF dopamine levels and frequency of HIV infection.

Authors:  Anne Horn; C Scheller; S du Plessis; R Burger; G Arendt; J Joska; S Sopper; C M Maschke; M Obermann; I W Husstedt; J Hain; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2016-12-01       Impact factor: 3.575

Review 7.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

8.  Methamphetamine enhances HIV infection of macrophages.

Authors:  Hao Liang; Xu Wang; Hui Chen; Li Song; Li Ye; Shi-Hong Wang; Yan-Jian Wang; Lin Zhou; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

Review 9.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

10.  Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse.

Authors:  Linda Chang; Gene-Jack Wang; Nora D Volkow; Thomas Ernst; Frank Telang; Jean Logan; Joanna S Fowler
Journal:  Neuroimage       Date:  2008-05-20       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.